Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

NCT07864207 is registered in ClinicalTrials.gov with IDP Discovery Pharma S.L. as lead sponsor.

NCT NCT07864207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07864207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)
Lead sponsor
IDP Discovery Pharma S.L.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 28, 2026
Completion date
July 30, 2028
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer ( sclc )